Join the webinar to explore Nightingale Health’s latest addition to our multiomics portfolio for medical research: proteomic biomarkers from Alamar’s NULISA CNS and Inflammation Panels.
Nightingale now offers the leading targeted metabolomics and proteomics platforms as a combined service for population health research. The long-standing value of our metabolomics platform across the disease spectrum is hereby complemented by ultra-sensitive biomarkers captured by Alamar’s NULISA proteomics assay. This provides unprecedented opportunities to study how systemic metabolism and vascular health relate to neurodegenerative diseases such as dementia.

The webinar will be run jointly by experts from Nightingale and Alamar. Learn how proteomics with attomolar sensitivity can detect the hottest blood biomarkers in neurology, such as brain-derived pTau, and understand how this opens possibilities for dissecting the relation between the health of heart and brain.

After the presentation, there will be time for questions.